Confronto

Glepaglutide vs. Bremelanotide

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

nessun dato

189691-06-3

Peso molecolare

nessun dato

1025.18 g/mol

Emivita

nessun dato

2.7 h

Sequenza

nessun dato

Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Meccanismo d'azione

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Bremelanotide

Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Glepaglutide	Bremelanotide
Australia	—	Limitato
Germania	Non approvato	Non approvato
Stati Uniti	Non approvato	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Glepaglutide and Bremelanotide?: Glepaglutide is classified as "Ricerca (altro)", while Bremelanotide is classified as "Ricerca (altro)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Glepaglutide or Bremelanotide?: The highest available evidence level is "RCT sull'uomo" for Glepaglutide and "RCT sull'uomo" for Bremelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Glepaglutide and Bremelanotide in Germany and the United States?: Germania: Glepaglutide — Non approvato, Bremelanotide — Non approvato. Stati Uniti: Glepaglutide — Non approvato, Bremelanotide — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Glepaglutide

Bremelanotide

Australia

—

Limitato

Germania

Non approvato

Stati Uniti

Non approvato

Su prescrizione

Frequently asked questions

What is the difference between Glepaglutide and Bremelanotide?

Glepaglutide is classified as "Ricerca (altro)", while Bremelanotide is classified as "Ricerca (altro)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Glepaglutide or Bremelanotide?

The highest available evidence level is "RCT sull'uomo" for Glepaglutide and "RCT sull'uomo" for Bremelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Glepaglutide and Bremelanotide in Germany and the United States?

Germania: Glepaglutide — Non approvato, Bremelanotide — Non approvato. Stati Uniti: Glepaglutide — Non approvato, Bremelanotide — Su prescrizione. These are factual summaries with source and review date on the individual pages.